Pharma Tariffs Would Hike Drug Costs By $51B Annually

Reuters reports:

A 25% U.S. tariff on pharmaceutical imports would increase U.S. drug costs by nearly $51 billion annually, boosting U.S. prices by as much as 12.9% if passed on, a report commissioned by the industry’s U.S. trade group and reviewed by Reuters shows.

The analysis, conducted by Ernst & Young, found the United States imported $203 billion in pharmaceutical products in 2023, with 73% coming from Europe — primarily Ireland, Germany and Switzerland. Total U.S. sales of finished pharmaceuticals that year were $393 billion.

The report, dated April 22 and not made public, was commissioned by the main U.S. pharmaceutical lobby, the Pharmaceutical Research and Manufacturers of America, whose members include Amgen (AMGN), Bristol Myers Squibb (BMY), Eli Lilly (LLY), and Pfizer (PFE), among others.

Read the full article.

Exclusive: US pharma tariffs would raise US drug costs by $51 billion annually, report finds https://t.co/Gf1Ifoxxlp https://t.co/Gf1Ifoxxlp

— Reuters (@Reuters) April 25, 2025